PTC-Guided Therapy for Peritoneal Mesothelioma | MicrobiomeTrials← Back to trialsNCT07330271
PTC-Guided Therapy for Peritoneal Mesothelioma
RecruitingNAINTERVENTIONAL
Trial Details
Start: 2025-12-02Est. Completion: 2029-11-01
Enrollment target: 347 participants Locations- Tsinghua University affiliated Beijing Tsinghua Changgung Hospital, Beijing, China
Other microbiome trials you might be interested in
Acinar Cell CarcinomaAdenoid Cystic CarcinomaAdrenal Cortical CarcinomaAdrenal Gland PheochromocytomaAnal Canal Neuroendocrine CarcinomaAnal Canal Undifferentiated CarcinomaAngiosarcomaApocrine NeoplasmAppendix Mucinous AdenocarcinomaBartholin Gland Transitional Cell CarcinomaBasal Cell CarcinomaBladder AdenocarcinomaBreast Metaplastic CarcinomaCervical AdenocarcinomaCholangiocarcinomaChordomaColorectal Squamous Cell CarcinomaDesmoid FibromatosisEndometrial Transitional Cell CarcinomaEndometrioid AdenocarcinomaEsophageal Neuroendocrine CarcinomaEsophageal Undifferentiated CarcinomaExtrahepatic Bile Duct CarcinomaExtramammary Paget DiseaseFallopian Tube AdenocarcinomaFallopian Tube Transitional Cell CarcinomaFibromyxoid TumorGallbladder CarcinomaGastric Neuroendocrine CarcinomaGastric Squamous Cell CarcinomaGastric Undifferentiated CarcinomaGastrointestinal Stromal TumorGestational Trophoblastic TumorGiant Cell CarcinomaHuman Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-TypeIntestinal Neuroendocrine CarcinomaIntrahepatic CholangiocarcinomaLung Neuroendocrine TumorLung Sarcomatoid CarcinomaMajor Salivary Gland CarcinomaMalignant Neoplasm of Unknown PrimaryMalignant Odontogenic NeoplasmMalignant Peripheral Nerve Sheath TumorMalignant Solid NeoplasmMalignant Testicular Sex Cord-Stromal TumorMetastatic Pituitary Neuroendocrine TumorMinimally Invasive Lung AdenocarcinomaMixed Mesodermal (Mullerian) TumorMucinous AdenocarcinomaMucinous CystadenocarcinomaNasal Cavity AdenocarcinomaNasal Cavity CarcinomaNasopharyngeal CarcinomaNasopharyngeal Low Grade Papillary AdenocarcinomaNasopharyngeal Undifferentiated CarcinomaOral Cavity CarcinomaOropharyngeal Undifferentiated CarcinomaOvarian AdenocarcinomaOvarian Germ Cell TumorOvarian Mucinous AdenocarcinomaOvarian Squamous Cell CarcinomaOvarian Transitional Cell CarcinomaPancreatic Acinar Cell CarcinomaPancreatic Neuroendocrine CarcinomaParagangliomaParanasal Sinus AdenocarcinomaParanasal Sinus CarcinomaParathyroid Gland CarcinomaPEComaPenile Squamous Cell CarcinomaPeritoneal Mesothelial NeoplasmPlacental ChoriocarcinomaPrimary Peritoneal High Grade Serous AdenocarcinomaPseudomyxoma PeritoneiRare DisorderScrotal Squamous Cell CarcinomaSeminal Vesicle AdenocarcinomaSeminomaSerous CystadenocarcinomaSmall Intestinal AdenocarcinomaSmall Intestinal Squamous Cell CarcinomaSpindle Cell NeoplasmTeratoma With Somatic-Type MalignancyTesticular Non-Seminomatous Germ Cell TumorThyroid Gland CarcinomaTracheal CarcinomaTransitional Cell CarcinomaUreter AdenocarcinomaUreter Squamous Cell CarcinomaUrethral AdenocarcinomaUrethral Squamous Cell CarcinomaVaginal AdenocarcinomaVaginal Squamous Cell Carcinoma, Not Otherwise SpecifiedVulvar Carcinoma
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclona…
Birmingham, United StatesEst. completion May 1, 2026
Mesothelin-Expressing TumorsEpithelial Ovarian CancerMalignant Pleural Mesothelioma, AdvancedMalignant Peritoneal Mesothelioma, AdvancedPancreatic Adenocarcinoma Advanced or MetastaticLung Adenocarcinoma MetastaticCholangiocarcinoma AdvancedCholangiocarcinoma Non-resectableMesothelin-expressing Advanced CancersMesothelin-positive Advanced Malignant Solid TumorsColorectal Cancer
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety,…
Denver, United StatesEst. completion Dec 2026